Justin Drake
Men with progressive metastatic prostate cancer are often treated with medicines that target androgen receptor (AR) pathways. These patients invariably develop resistance to current AR treatments (e.g., Lupron, Zytiga®, Xtandi®)....Read More
Martin Sanda
Dr. Sanda and his cross-disciplinary team of nano-material chemists and immunologists are developing a new immunotherapy with the potential to boost a patient’s immune system to fight cancer. This new...Read More
Mark Rubin, MD
Dr. Mark A. Rubin is a professor of oncology and Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Dr. Rubin is a recognized world leader in...Read More
William G. Nelson
One of the causes for the initiation of cancer is the switching off or complete shutdown of certain critical genes (gene silencing) that should remain active. Tumor cells also use...Read More
Christopher J. Logothetis
Despite initial response, most prostate cancers will invariably become resistant to available therapies. Therefore, it is essential to understand these mechanisms of resistance operating in tumor cells as this will...Read More
Heather Cheng
Although family history is well-established as a risk factor for development of prostate cancer, scientists currently lack a comprehensive understanding of underlying genetic causes. Dr. Heather Cheng is coordinating a...Read More
Rahul Aggarwal, MD
Dr. Rahul Aggarwal is a Medical Oncologist within the Division of Hematology/Oncology at the University of San Francisco, California (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr. Aggarwal also serves...Read More
Dr. Glenn Liu
As prostate cancer advances and spreads, it homes in on the bones. Monitoring the establishment and spread of cancerous tumors in the bone poses a major challenge. It is also...Read More
Philip G. Febbo
Drs. Febbo and Higano propose a phase II trial of the experimental medication, XL184 (Cabozantinib) that has shown very promising results in reducing bone and soft tissue metastases in patients...Read More
Wassim Abida, MD, PhD
Dr. Abida is a medical oncologist and physician-scientist in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), where his focus is on prostate cancer clinical investigation, developmental...Read More